Skip to content
DataLookout
Menu

NCT05976763

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 27 versions: 26 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 238 → 242 locations
  2. Notable Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 6 of 6 entries
    • Study description revised
    • Site details revised at 31 of 238 sites
  3. Minor Site details revised at 3 of 238 sitesv25
  4. Minor Study sites: 237 to 238v24
  5. Notable Eligibility criteria shortened, about 6 words
    • Study description expanded, about 65 words
    v23
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Site details revised at 8 of 237 sitesv22
  2. Minor Study sites: 236 to 237v21
  1. Minor Trial sites expanded: 233 → 236 locationsv20
  2. Minor Study sites: 231 to 233v19
  3. Minor Study sites: 230 to 231v18
  4. Minor Study sites: 228 to 230v17
  5. Minor Study sites: 227 to 228v16
  6. Minor Site details revised at 2 of 227 sitesv15
  7. Minor Study sites: 218 to 227v14
  8. Minor Study sites: 213 to 218v13
  9. Minor Study sites: 209 to 213v12
  10. Minor Study sites: 204 to 209v11
  11. Notable Start date: Sep 8, 2023 to Oct 20, 2023
    • Site contacts updated at 203 of 204 sites
    v10
  12. Minor Study sites: 178 to 204v9
  13. Minor Study sites: 155 to 178v8
  14. Minor Study sites: 138 to 155v7
  15. Minor Study sites: 104 to 138v6
  16. Minor Study sites: 62 to 104v5
  17. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 62
    v4
  18. Notable Start date: Aug 8, 2023 to Sep 8, 2023v2
  19. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-free survival (PFS) 1 (Arm A)
Timeframe: Time from randomization until the earlier of first progression or death from any cause, assessed up to 10 years
Progression-free survival (PFS) 2 (Arm B)
Timeframe: Time from randomization until the earlier of second progression or death from any cause, assessed up to 10 years

Secondary (6)

Overall survival (OS) (Arms A and B)
Incidence of adverse events
Overall response rate (ORR, complete + partial remission)
Complete response rate (CR)
Event-free survival (EFS) 1
Show 1 moreShow less
Event-free survival (EFS) 2

Arms and interventions

Induction therapy (Zanubrutinib, rituximab)Experimental

Patients receive zanubrutinib PO and rituximab IV on study. Patients undergo bone marrow biopsy and FDG PET/CT or CT throughout the trial. Patients may also undergo EDG and/or colonoscopy on study as clinically indicated. Patients may optionally undergo blood sample collection throughout the trial.

Arm A (Zanubrutinib)Experimental

Patients receive zanubrutinib PO until first disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial.

ARM B (Observation)Active comparator

Patients undergo observation until first disease progression and then receive zanubrutinib PO until second disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial.

Drugs: Zanubrutinib

Biologicals: Rituximab

Other: Patient Observation, Fludeoxyglucose F-18, Questionnaire Administration

Procedures: Bone Marrow Biopsy, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging, Esophagogastroduodenoscopy, Colonoscopy, Biospecimen Collection

Sites

242 sites in 1 country